14703-79-8

Basic information

• Product Name: 3-(Methylamino)-4-nitrophenol
• Synonyms: 3-(Methylamino)-4-nitrophenol
• CAS NO: 14703-79-8
• Molecular Formula: C₇H₈N₂O₃
• Molecular Weight: 168.15
• Mol File: 14703-79-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 384.1 °C at 760 mmHg
• Flash Point: 186.1 °C
• Appearance: /
• Density: 1.411 g/cm³
• Vapor Pressure: 1.9E-06mmHg at 25°C
• Refractive Index: 1.665
• CAS DataBase Reference: 3-(Methylamino)-4-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Methylamino)-4-nitrophenol(14703-79-8)
• EPA Substance Registry System: 3-(Methylamino)-4-nitrophenol(14703-79-8)

Safety Data

• Hazardous Substances Data: 14703-79-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H8N2O3/c1-8-6-4-5(10)2-3-7(6)9(11)12/h2-4,8,10H,1H3

Upstream product

• 491-11-2 3-chloro-4-nitrophenol 
• 74-89-5 methylamine 
• 394-41-2 3-fluoro-4-nitrophenol 

Downstream Products

• 63810-42-4 [3-(N-methylamino)4-nitro] phenyl N,N-diethylcarbamylmethyl ether 
• 50591-23-6 1-methyl-1H-benzo[d]imidazol-6-ol 

Relevant articles and documents

RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF

The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections.

ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS

The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.